Compounded semaglutide — the safety problem and why we don't prescribe it

What 'compounded' actually means here

'Compounded' has a legitimate meaning in pharmacy — the preparation of an individualised medicine for a specific patient based on a prescriber's order, where a licensed product doesn't exist or isn't suitable. Specials pharmacies in the UK do this under regulated conditions for genuine clinical need.

What's being sold online as 'compounded semaglutide' is something different. It's typically:

• Bulk active pharmaceutical ingredient (API) sourced from research-grade or unregulated suppliers, often in China or India, then reconstituted with bacteriostatic water.
• Or diluted licensed semaglutide, repackaged into vials by parties without manufacturing authorisation.
• Or unknown synthetic peptides marketed as semaglutide.
• Sold via 'telehealth' websites, social media, or directly from non-pharmacy sources.
• Marketed at prices a fraction of licensed Wegovy or Ozempic.
• Not MHRA-licensed for use in the UK.
• Not dispensed by GPhC-registered pharmacies (or, when claimed to be, often under spurious arrangements).

This is not the same as the legitimate UK Specials pharmacy compounding pathway. The use of 'compounded' is largely marketing.

The US context vs the UK context

In the US, large-scale semaglutide compounding by 503A and 503B pharmacies was permitted under a specific FDA Drug Shortage provision while licensed semaglutide was on the shortage list. That provision ended in 2025 when the shortage was officially resolved, and the FDA has been actively enforcing against continued compounding for weight loss.

The UK never had an equivalent provision. There has been no regulatory pathway in the UK for the compounded semaglutide products sold online to patients. They have always been outside the licensed supply chain, regardless of what the marketing claims.

Why prices look attractive

A typical pricing comparison patients see:

• Licensed Wegovy or Ozempic via a responsible UK programme: significant monthly cost.
• Compounded semaglutide via an online vendor: often less than half.

The price difference is real — but it reflects what's missing, not efficiency. The licensed price covers:

• The clinical trials that established safety and efficacy.
• MHRA regulatory approval and ongoing post-market surveillance.
• Pharmaceutical-grade manufacturing under inspected GMP conditions.
• Batch-by-batch quality testing for identity, potency, sterility, and contaminants.
• The supply chain (cold chain, traceability, recall capability).
• The prescriber's clinical assessment, consultation, monitoring, and indemnity.
• The GPhC-registered pharmacy dispensing infrastructure.
• Patient safety reporting (Yellow Card) and post-market follow-up.

The compounded product covers some of the API cost — maybe — and not much else. The savings are the absent safety infrastructure.

What's actually in those vials

Independent testing of compounded GLP-1 products has found:

• Wide variation in actual semaglutide content vs labelled content (sometimes well above, sometimes well below).
• Bacterial contamination, particularly in products reconstituted with non-sterile water or stored incorrectly.
• Endotoxin contamination at concerning levels.
• The wrong peptide entirely.
• Mislabelled doses, including products labelled in milligrams that actually contain micrograms (or vice versa) — a recipe for either no effect or massive overdose.
• In some samples, insulin contamination — which is potentially lethal in a patient who's been given a 'GLP-1' product.

This isn't theoretical. The MHRA and the FDA have both issued warnings. Multiple poisoning events linked to compounded or counterfeit GLP-1 products have been reported internationally.

The harms patients have experienced

Reported harm patterns:

• Severe hypoglycaemia. From contamination with insulin or sulfonylurea drugs. Several hospitalisations and at least some deaths.
• Severe gastrointestinal symptoms. Beyond the expected GLP-1 side effect profile — often from dosing errors (much higher than intended).
• Bacterial infections at injection sites. From non-sterile manufacture or storage.
• Severe allergic reactions. Including anaphylaxis to unknown contaminants.
• Treatment failure. Patients spending months on what they think is GLP-1 medication while losing no weight — because the product was inactive, mislabelled, or sub-potent.
• No recourse when things go wrong. Non-regulated vendors disappear; no recall, no insurance, no compensation.

The regulatory position in the UK

Tirzepatide (Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda) are MHRA-licensed prescription-only medicines (POMs) in the UK. They can only be:

• Prescribed by an authorised prescriber after a clinical consultation.
• Dispensed by a GPhC-registered pharmacy in the UK against a valid UK prescription.
• In the licensed formulations from the manufacturers (Eli Lilly for tirzepatide; Novo Nordisk for semaglutide and liraglutide).

Anything outside this pathway is non-compliant with UK medicines regulation. The MHRA has been actively investigating online suppliers, and the GPhC has been disciplining pharmacists involved in non-compliant supply.

What about 'private prescription' compounded products?

Some online services claim to dispense compounded semaglutide on a 'private prescription'. The combination of a real UK private prescription + a UK GPhC-registered pharmacy + the licensed product would be legitimate. The combination of a 'private prescription' + compounded semaglutide is generally not, because compounded semaglutide for weight loss is not a recognised UK Special and there's no clinical justification for it when the licensed product is available.

If you're buying from a website that:

• Doesn't have a UK-registered prescriber.
• Doesn't have a GPhC pharmacy registration that you can verify on the GPhC register.
• Sends product from outside the UK.
• Doesn't conduct a meaningful clinical consultation.
• Doesn't require ID verification.
• Doesn't offer ongoing clinical support.
• Sells vials rather than licensed branded pens.

... you're not buying licensed medication. The legal framework is set up for the patient to lose if something goes wrong.

How to spot a non-legitimate supplier

Red flags:

• Prices substantially below licensed product pricing for an apparently similar dose.
• Sale of vials and bacteriostatic water rather than pre-filled MHRA-licensed pens.
• 'Research-grade', 'research-only', or 'not for human consumption' disclaimers in small print.
• Use of names like 'Generic Ozempic', 'Sema-Lite', 'OzempLite', 'WeGo' — imitation branding that doesn't match the actual licensed product.
• Shipping from outside the UK, especially from countries known for unregulated pharmaceutical manufacture.
• No GPhC pharmacy number, or a number that doesn't match the website on the GPhC register lookup.
• No real consultation — just a checkbox health questionnaire.
• Pressure to buy multi-month supplies upfront.
• Reviews that read suspiciously similar across products.
• Absence of any sharps disposal information or storage instructions.

What to do if you've been using it

If you've been using compounded or non-regulated semaglutide:

1. Stop using it. Don't take the next dose. Don't dispose of any remaining product yet — keep it with packaging so a clinician can identify what you've been on.
2. Get a clinical review. Tell your GP and/or a private prescriber what you've been using. Bring the vial and any documentation. Be honest — you won't be judged, but the clinician needs the full picture.
3. Get baseline bloods if not done recently. Full blood count, U&Es, LFTs, HbA1c, lipid panel. Useful baseline and helps rule out any harm from contamination.
4. Discuss legitimate transition. If you're appropriate for ongoing GLP-1 medication, a clinician can arrange a regulated supply via the proper pathway. Don't 'switch' between products without clinical guidance.
5. Report to the MHRA Yellow Card scheme if you've experienced any side effects. This helps the wider patient safety picture.
6. Don't restart unsupervised. The medication still works if it's the real product. The issue isn't 'GLP-1 medication is bad' — it's 'this specific supply chain is unsafe'.

The legitimate UK pathway

If you want to use GLP-1/GIP medication for weight management:

• NHS pathway. If you meet criteria (BMI ≥35 / ≥32.5 in some ethnic groups, with at least one comorbidity), ask your GP for referral to specialist weight management. See NHS Tier 3 vs private weight loss.
• Private pathway. A consultation with a UK-registered prescriber (often a GP, pharmacist independent prescriber, or specialist) at a GPhC-registered pharmacy or clinic. The licensed pre-filled pens (Wegovy, Mounjaro) are dispensed against a valid UK prescription as part of a structured programme.
• For more on the choices. See Mounjaro explained, Wegovy explained, and Saxenda vs Wegovy vs Mounjaro.

The bigger picture

The compounded semaglutide market exists because licensed GLP-1 medication is expensive and demand outstrips supply at times. That's a real problem, and it's understandable why a cheaper-looking option is tempting. But the cost difference reflects absent safety infrastructure, not innovation. The patient bears all the risk and has no recourse.

If cost is the barrier, the right conversation is about NHS eligibility, programme structure, or modified treatment plans — not about cheaper unregulated supply. Most pharmacist-led services will have an honest conversation with you about whether private treatment fits your budget. We'd rather you not start than start with the wrong supply chain.

The next step

If you've been considering a compounded product, or you've been using one and want to transition to regulated care safely, the most useful single step is a consultation. We'll review your history, work through what's possible within your circumstances, and — if appropriate — start you on a proper structured programme with traceable medication and the safety infrastructure that should sit around any prescription.